INTRODUCTION: Cancer stem cell-related (CSC) markers like CD133 and nestin have been suggested as a novel type of prognostic markers in gliomas. However no single CSC-related marker is currently used in clinical decisions. The aim of this study was to investigate the prognostic potential of CD133 and nestin separately and in combination using a novel quantitative approach in a well-characterized population-based cohort of glioma patients. METHODS: Using computer-based systematic and random sampling the expression of CD133 and nestin were investigated in paraffin sections from 239 primary gliomas (WHO grade II-IV .17) , and there was no association with overall survival (OS) or progression-free survival (PFS). High levels of co-localization were associated with poor PFS in patients with WHO grade II tumours (HR 3.09, 95% CI 1.05-9.11, p ¼ 0.04), but not in patients with WHO grade III (HR 1.27, 95% CI 0.41-3.98, p ¼ 0.68) and IV tumours (HR 0.97, 95% CI 0.66-1.43, p ¼ 0.88). Co-localization was not associated with overall survival. CONCLUSION: CD133 was not an independent prognostic factor, but a high level of nestin was associated with poor PFS in patients with WHO grade II tumours. High levels of co-localization were associated with poor PFS in patients with WHO grade II tumours but did not provide independent prognostic value. The combination of double-immunofluorescence and automated analysis seems to be a feasible and reproducible approach for future investigation of potential prognostic biomarkers.
